1. Home
  2. SFBS vs ERAS Comparison

SFBS vs ERAS Comparison

Compare SFBS & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ServisFirst Bancshares Inc.

SFBS

ServisFirst Bancshares Inc.

HOLD

Current Price

$87.61

Market Cap

4.4B

Sector

Finance

ML Signal

HOLD

Logo Erasca Inc.

ERAS

Erasca Inc.

HOLD

Current Price

$19.11

Market Cap

4.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SFBS
ERAS
Founded
2005
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.4B
4.0B
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
SFBS
ERAS
Price
$87.61
$19.11
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
12
Target Price
$93.00
$14.25
AVG Volume (30 Days)
297.6K
5.6M
Earning Date
04-20-2026
05-08-2026
Dividend Yield
1.94%
N/A
EPS Growth
21.63
36.23
EPS
1.52
N/A
Revenue
N/A
N/A
Revenue This Year
$32.30
N/A
Revenue Next Year
$10.30
N/A
P/E Ratio
$57.25
N/A
Revenue Growth
N/A
N/A
52 Week Low
$67.20
$1.33
52 Week High
$90.64
$24.28

Technical Indicators

Market Signals
Indicator
SFBS
ERAS
Relative Strength Index (RSI) 58.14 59.23
Support Level $78.72 $17.63
Resistance Level $88.96 $21.60
Average True Range (ATR) 2.10 1.29
MACD -0.14 -0.16
Stochastic Oscillator 64.94 41.03

Price Performance

Historical Comparison
SFBS
ERAS

About SFBS ServisFirst Bancshares Inc.

Servisfirst Bancshares Inc is a bank holding company whose business is conducted by its wholly owned subsidiary. Through the subsidiary, it offers various banking services to individual and corporate customers in Birmingham, Florida, Georgia, North Carolina, South Carolina, Tennessee, and Virginia. Its various products and service offerings include commercial, consumer, and other loans; accepting deposits; providing electronic banking services, such as online and mobile banking, including remote deposit capture; delivering treasury and cash management services; and providing banking services to other financial institutions. The company operates as a single reportable segment, with a majority of its revenue being derived from the business of banking.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.

Share on Social Networks: